ClinicalTrials.gg
CompletedNCT02475681ElevateTNUpdated Nov 16, 2026Results posted

Acalabrutinib, Obinutuzumab and Chlorambucil in Treatment naïve CLL

A Phase 3 interventional study of Acalabrutinib and Obinutuzumab in Chronic Lymphocytic Leukemia, sponsored by Acerta Pharma BV. Completed at 155 sites in 18 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-16.

Sponsored by Acerta Pharma BV (part of AstraZeneca) · Phase 3, Interventional, and Treatment

Updated Nov 16, 2026Now CompletedStudy completion moved+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
535
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 39 studies testing acalabrutinib in Leukemia, Lymphocytic, Chronic, B-Cell — 11 open to participants now, 28 under way, 6 of them phase 3. acalabrutinib · Leukemia, Lymphocytic, Chronic, B-Cell.

Enrollment
4th of 39
535 · median 61
Started
2015
with 3 others
Phase 3
9 of 39
1 open now
Registered
4th of 39
by date
Lead sponsor
9 of 39
Acerta Pharma BV

Among the 39 studies testing acalabrutinib in Leukemia, Lymphocytic, Chronic, B-Cell, this one is the 4th largest by enrollment, is one of 4 that started in 2015, is one of 9 in phase 3, and was the 4th registered.

Leukemia, Lymphocytic, Chronic, B-Cell

2,036 studies on the registry are indexed under Leukemia, Lymphocytic, Chronic, B-Cell; 236 are open to participants now.

Browse Leukemia, Lymphocytic, Chronic, B-Cell studies →

Open to participants now

11 of the 39 studies testing acalabrutinib in Leukemia, Lymphocytic, Chronic, B-Cell are open now, in 12 countries. Recruiting first, the newest first:

6 more — sign in →

By country, each count listing its studies:

All 11 open studies →

About acalabrutinib

acalabrutinib: first FDA approval 2017 (CALQUENCE), first EMA approval 2020. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 187 Leukemia, Lymphocytic, Chronic, B-Cell studies recruiting now, 150 (80%) set no upper age limit and 15 (8%) stop at 75 or younger; 17 take children under 18; 12 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 39 studies testing acalabrutinib in Leukemia, Lymphocytic, Chronic, B-Cell, or all of them as a file.
02

Study summary

This Primary objective is evaluating the efficacy of obinutuzumab in combination with chlorambucil (Arm A) compared with acalabrutinib in combination with obinutuzumab (Arm B) for the treatment of previously untreated chronic lymphocytic leukemia (CLL). Secondary objectives: 1) To evaluate the efficacy of obinutuzumab in combination with chlorambucil (Arm A) versus acalabrutinib monotherapy (Arm C) based on IRC assessment of PFS per IWCLL 2008 criteria.

2)To compare obinutuzumab plus chlorambucil (Arm A) versus acalabrutinib plus obinutuzumab (Arm B) and obinutuzumab plus chlorambucil (Arm A) versus acalabrutinib monotherapy (Arm C) in terms of: IRC-assessed objective response rate (ORR); Tine to next treatment (TTNT); Overall Survival (OS)

Read the detailed description

ELEVATE-TN is a global, phase 3, multicenter, open-label study in patients with treatment-naive chronic lymphocytic leukemia (CLL). Study enrollment is completed. The study randomized a total of 535 subjects in 142 study sites in 18 countries between 14 September 2015 through 08 February 2017. Patients were randomly assigned to receive Acalabrutinib and Obinutuzumab, Acalabrutinib monotherapy, or Obinutuzumab and oral Chlorambucil. The primary endpoint was progression-free survival between the two combination-therapy groups, defined as the time from randomization until disease progression by use of iwCLL 2008 criteria, or death, assessed by independent review committee (IRC). Crossover to Acalabrutinib was allowed in patients who progressed on Obinutuzumab-Chlorambucil.

The results of this study provide new evidence for therapy in patients with treatment-naive chronic lymphocytic leukemia by showing the efficacy of Acalabrutinib used with or without Obinutuzumab compared with chemoimmunotherapy.

Currently the study is in maintenance phase, with more than 430 subjects on study, to generate more evidence. We are not expecting any significant change in the near future.

03

Conditions studied

  • Chronic Lymphocytic Leukemia
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Men and women:

    a. ≥ 65 years of age OR b. > 18 and \< 65 years of age, provided that they meet at least one of the following criteria: i. 30 to 69 mL/min using the Cockcroft-Gault equation ii. A score higher than 6 on the CIRS-G (Appendix L).

  2. performance status of 0, 1, or 2.
  3. Diagnosis of CD20+ CLL that meets published diagnostic criteria (Hallek 2008):

    1. Monoclonal B cells (either kappa or lambda light chain restricted) that are clonally co-expressing ≥ 1 B-cell marker (CD19, CD20, or CD23) and CD5.
    2. Prolymphocytes may comprise ≤ 55% of blood lymphocytes.
    3. Presence of ≥ 5 x 109 B lymphocytes/L (5000 μL) in the peripheral blood (at any point since diagnosis)
  4. Active disease meeting ≥ 1 of the following IWCLL 2008 criteria for requiring treatment:

    1. Evidence of progressive marrow failure as manifested by the development of, or worsening of, anemia ( \< 10 g/dL) and/or thrombocytopenia ( \< 100,000/μL).
    2. Massive (i.e., ≥ 6 cm below the left costal margin), progressive, or symptomatic splenomegaly.
    3. Massive nodes (i.e., ≥ 10 cm in the longest diameter), progressive, or symptomatic lymphadenopathy.
    4. Progressive lymphocytosis with an increase of > 50% over a 2-month period or a LDT of \< 6 months. LDT may be obtained by linear regression extrapolation of ALC obtained at intervals of 2 weeks over an observation period of 2 to 3 months. In subjects with initial blood lymphocyte counts of \< 30 x 109/L (30,000/μL), LDT should not be used as a single parameter to define indication for treatment. In addition, factors contributing to lymphocytosis or lymphadenopathy other than CLL (e.g., infections) should be excluded.
    5. anemia and/or thrombocytopenia that is poorly responsive to standard therapy.
    6. Constitutional symptoms documented in the subject's chart with supportive objective measures, as appropriate, defined as ≥ 1 of the following disease-related symptoms or signs:

    i. Unintentional weight loss ≥ 10% within the previous 6 months before Screening.

    ii. Significant fatigue (i.e., ECOG performance status 2; inability to work or perform usual activities).

    iii. Fevers higher than 100.5°F or 38.0°C for 2 or more weeks before Screening without evidence of infection.

    iv. Night sweats for > 1 month before Screening without evidence of infection.

  5. This criterion was deleted as of Protocol Amendment 3.
  6. Meet the following laboratory parameters:

    1. ≥ 750 cells/μL (0.75 x 109/L), or ≥ 500 cells/μL (0.50 x 109/L) in subjects with documented bone marrow involvement, and independent of growth factor support 7 days before assessment.
    2. Platelet count ≥ 50,000 cells/μL (50 x 109/L), or ≥ 30,000 cells/μL (30 x 109/L) in subjects with documented bone marrow involvement, and without transfusion support 7 days before assessment. Subjects with transfusion-dependent thrombocytopenia are excluded.
    3. Serum and ALT/SGPT ≤ 3.0 x .
    4. Total ≤ 1.5 x ULN.
    5. Estimated creatinine clearance (i.e., using Cockcroft-Gault) ≥ 30 mL/min
  7. Able to receive all outpatient treatment, all laboratory monitoring, and all radiologic evaluations.
  8. Women who are sexually active and can bear children must agree to use highly effective forms of while on the study and for 2 days after the last dose of acalabrutinib or 18 months after the last dose of obinutuzumab in combination with chlorambucil, whichever is longer. Highly effective forms of contraception are defined in Section 6.4.4.
  9. Men who are sexually active and can beget children must agree to use highly effective forms of contraception during the study and for 90 days after the last dose of obinutuzumab or chlorambucil, whichever is later. Highly effective forms of contraception are defined in Section 6.4.4.
  10. Men must agree to refrain from sperm donation during the study and for 90 days after the last dose of obinutuzumab or chlorambucil, whichever is later.
  11. Must be willing and able to adhere to the study visit schedule, understand and comply with other protocol requirements, and provide written and authorization to use protected health information (in accordance with national and local subject privacy regulations). Note vulnerable subjects, as defined in International Conference on Harmonisation (ICH) GCP, are not allowed on this protocol (e.g., prisoners or institutionalized subjects).

Exclusion criteria

Exclusion Criteria:

  1. Any prior systemic treatment for CLL (note: Prior localized radiotherapy is allowed).
  2. Known CNS lymphoma or leukemia.
  3. Known prolymphocytic leukemia or history of, or currently suspected, Richter's syndrome.
  4. Missing or incomplete documentation of FISH results reflecting the presence or absence of 17p del and the percentage of cells with the deletion in subject records before randomization.
  5. Uncontrolled AIHA or ITP defined as declining or count secondary to destruction within the screening period or requirement for high doses of (> 20 mg daily of prednisone daily or equivalent).
  6. Corticosteroid use > 20 mg within 1 week before first dose of study drug, except as indicated for other medical conditions such as inhaled steroid for asthma, topical steroid use, or as premedication for administration of study drug or contrast. For example, subjects requiring steroids at daily doses > 20 mg prednisone equivalent systemic exposure daily, or those who are administered steroids for leukemia control or WBC count lowering are excluded.
  7. Major surgery within 4 weeks before first dose of study drug.
  8. History of prior except for the following:

    1. Malignancy treated with curative intent and with no evidence of active disease present for more than 3 years before Screening and felt to be at low risk for recurrence by treating physician.
    2. Adequately treated lentigo maligna melanoma without current evidence of disease or adequately controlled non-melanomatous skin cancer.
    3. Adequately treated cervical carcinoma in situ without current evidence of disease.
  9. Significant cardiovascular disease such as uncontrolled or symptomatic arrhythmias, congestive heart failure, or myocardial infarction within 6 months of screening, or any Class 3 or 4 cardiac disease as defined by the Functional Classification, or > 480 msec at screening.
  10. Unable to swallow capsules or malabsorption syndrome, disease significantly affecting gastrointestinal function, or resection of the stomach or small bowel or gastric bypass, symptomatic inflammatory bowel disease, or partial or complete bowel obstruction.
  11. Uncontrolled active systemic fungal, bacterial, viral, or other infection (defined as exhibiting ongoing signs/symptoms related to the infection and without improvement, despite appropriate antibiotics or other treatment) or ongoing intravenous anti-infective treatment.
  12. Known history of infection with . 13. Vaccinated with live, attenuated vaccines within 4 weeks of first dose of study drug.

14. Serologic status reflecting active or C infection. Subjects with hepatitis B core antibody positive who are surface antigen negative or who are antibody positive will need to have a negative PCR result before randomization. Those who are hepatitis B surface antigen positive or hepatitis B PCR positive and those who are hepatitis C PCR positive will be excluded.

15. History of stroke or intracranial hemorrhage within 6 months before randomization.

16. Known history of a bleeding diathesis (e.g., hemophilia, von Willebrand disease).

17. Requires or receiving anticoagulation with warfarin or equivalent vitamin K antagonists (e.g., phenprocoumon) within 7 days of first dose of study drug.

18. Requires treatment with proton-pump inhibitors (e.g., omeprazole, esomeprazole, lansoprazole, dexlansoprazole, rabeprazole, or pantoprazole).

19. Breast feeding or pregnant. 20. Current life-threatening illness, medical condition, or organ system dysfunction which, in the Investigator's opinion, could compromise the subject's safety or put the study at risk.

21. Concurrent participation in another therapeutic clinical trial. 22. Requires treatment with a strong inhibitor/inducer. 23. Presence of a gastrointestinal ulcer diagnosed by endoscopy within 3 months before screening.

Terms in these criteria, in plain language(20)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
535 participants (actual)

Study arms

  • Active comparator
    Arm A - Obinutuzumab in Combination with Chlorambucil

    Obinutuzumab IV infusions will be administered over a total of 6 treatment cycles starting at Cycle 1 Day 1. Chlorambucil will be orally administered on Days 1 and 15 of Cycles 1 through 6.

    Drug: Obinutuzumab · Drug: Chlorambucil

  • Experimental
    Arm B - Acalabrutinib in Combination with Obinutuzumab

    Obinutuzumab IV infusions will be administered over a total of 6 treatment cycles starting at Cycle 2 Day 1. Acalabrutinib (ACP-196) will be orally administered starting on Cycle 1 Day 1. Daily administration of Acalabrutinib (ACP-196) will continue until disease progression or unacceptable toxicity.

    Drug: Acalabrutinib · Drug: Obinutuzumab

  • Experimental
    Arm C - Acalabrutinib Monotherapy

    Acalabrutinib (ACP-196) will be orally administered on Cycle 1 Day 1 until disease progression or unacceptable toxicity.

    Drug: Acalabrutinib

Interventions

06

What researchers measure

Primary outcomes

  1. Progression-free Survival by IRC (Independent Review Committee) Assessment in Arm A Compared to Arm B

    To evaluate the efficacy of obinutuzumab in combination with chlorambucil (Arm A) compared with acalabrutinib in combination with obinutuzumab (Arm B) based on IRC assessment of progression-free survival (PFS) per International Workshop on Chronic Lymphocytic Leukemia criteria (IWCLL; Hallek et al. 2008) with incorporation of the clarification for treatment-related lymphocytosis (Cheson et al. 2012), hereafter referred to as IWCLL 2008 criteria, in subjects with previously untreated CLL. PFS, defined as the time from date of randomization to the date of first IRC-assessed disease progression or death due to any cause, whichever comes first.

    Time frame: IRC assessments were done from randomization date until disease progression or death or IRC discontinuation date on 08Feb2019 (as the IA based on this data cutoff date showed the study crossing superiority boundary) whichever comes first up to 40 months.

Secondary outcomes

  1. Progression-free Survival by IRC Assessment Arm A Versus Arm C

    To evaluate the efficacy of obinutuzumab in combination with chlorambucil (Arm A) compared with acalabrutinib monotherapy (Arm C) based on IRC assessment of progression-free survival (PFS) per International Workshop on Chronic Lymphocytic Leukemia criteria (IWCLL; Hallek et al. 2008) with incorporation of the clarification for treatment-related lymphocytosis (Cheson et al. 2012), hereafter referred to as IWCLL 2008 criteria, in subjects with previously untreated CLL. PFS, defined as the time from date of randomization to the date of first IRC-assessed disease progression or death due to any cause, whichever comes first.

    Time frame: IRC assessments were done from randomization date until disease progression or death or IRC discontinuation date on 08Feb2019 (as the IA based on this data cutoff date showed the study crossing superiority boundary) whichever comes first up to 40 months.

  2. IRC-assessed Objective Response Rate (ORR) in Arm A Versus Arm B and Arm A Versus Arm C

    ORR was defined as the proportion of subjects who achieved a best response of CR, CRi, nPR, or PR at or before initiation of subsequent anticancer therapy. ORR including PRL was defined as the proportion of subjects who achieved a best response of CR, CRi, nPR, PR or PRL at or before initiation of subsequent anticancer therapy

    Time frame: IRC assessments were done from randomization date until disease progression or death or IRC discontinuation date on 08Feb2019 (as the IA based on this data cutoff date showed the study crossing superiority boundary) whichever comes first up to 40 months.

  3. Time to Next Treatment (TTNT) in Arm A Versus Arm B and Arm A Versus Arm C

    TTNT was defined as the time from randomization to start date of non-protocol specified subsequent anticancer therapy for CLL or death due to any cause, whichever came first. TTNT was analyzed in the same fashion as that for the primary efficacy analysis

    Time frame: From randomization date to start of non-protocol specified subsequent anticancer therapy for CLL or death due to any cause, whichever came first assessed up to 40 months of follow-up.

  4. Overall Survival (OS) in Arm A Versus Arm B and Arm A Versus Arm C

    OS was defined as the time from the date of randomization to death due to any cause.

    Time frame: From randomization date until death, withdrawal by subject, lost to follow-up, or by analysis data cut off date on 08Feb2019 whichever comes first up to 40 months of follow-up.

07

Results

Posted Jan 10, 2023

Participant flow

A randomized, multicenter, open-label, 3 arm phase 3 study of Obinutuzumab in combination with Chlorambucil (Chlb+Obin), Acalabrutinib in combination with Obinutuzumab (Acala+Obin), and Acalabrutinib monotherapy (Acala) in subjects with previously untreated chronic lymphocytic leukemia. A total of 535 subjects recruited from 142 sites in 18 countries were randomized (1:1:1) as follows: 179/179 /177 subjects in Acla+Obin arm / Acala arm / Chlb+Obin arm respectively.

Participant flow — Overall Study
MilestoneArm A: Obinutuzumab in Combination With ChlorambucilArm B: Acalabrutinib in Combination With ObinutuzumabArm C: Acalabrutinib Monotherapy
Started177179179
Crossed over from arm a to arm c4500
Completed14500
Not completed32179179
Withdrew: Death1669
Withdrew: Physician decision031
Withdrew: Withdrawal by subject1269
Withdrew: Lost to follow-up213
Withdrew: Ongoing in study0163157
Withdrew: Reasons other than above listed200

Outcome measures

PrimaryProgression-free Survival by IRC (Independent Review Committee) Assessment in Arm A Compared to Arm B

To evaluate the efficacy of obinutuzumab in combination with chlorambucil (Arm A) compared with acalabrutinib in combination with obinutuzumab (Arm B) based on IRC assessment of progression-free survival (PFS) per International Workshop on Chronic Lymphocytic Leukemia criteria (IWCLL; Hallek et al. 2008) with incorporation of the clarification for treatment-related lymphocytosis (Cheson et al. 2012), hereafter referred to as IWCLL 2008 criteria, in subjects with previously untreated CLL. PFS, defined as the time from date of randomization to the date of first IRC-assessed disease progression or death due to any cause, whichever comes first.

Time frame:
IRC assessments were done from randomization date until disease progression or death or IRC discontinuation date on 08Feb2019 (as the IA based on this data cutoff date showed the study crossing superiority boundary) whichever comes first up to 40 months.
Reported as:
Median · Months
Progression-free Survival by IRC (Independent Review Committee) Assessment in Arm A Compared to Arm B
MonthsArm A: Obinutuzumab in Combination With ChlorambucilArm B: Acalabrutinib in Combination With Obinutuzumab
Progression-free Survival by IRC (Independent Review Committee) Assessment in Arm A Compared to Arm B22.6 (20.2 to 27.8)NA (NA to NA)
Statistical analysis
  • Arm A: Obinutuzumab in Combination With Chlorambucil vs Arm B: Acalabrutinib in Combination With Obinutuzumab · Log Rank · p = <0.0001 · Hazard ratio (hr): 0.1 · 95% CI 0.06 to 0.17Stratified by randomization stratification factors as recorded in IXRS
SecondaryProgression-free Survival by IRC Assessment Arm A Versus Arm C

To evaluate the efficacy of obinutuzumab in combination with chlorambucil (Arm A) compared with acalabrutinib monotherapy (Arm C) based on IRC assessment of progression-free survival (PFS) per International Workshop on Chronic Lymphocytic Leukemia criteria (IWCLL; Hallek et al. 2008) with incorporation of the clarification for treatment-related lymphocytosis (Cheson et al. 2012), hereafter referred to as IWCLL 2008 criteria, in subjects with previously untreated CLL. PFS, defined as the time from date of randomization to the date of first IRC-assessed disease progression or death due to any cause, whichever comes first.

Time frame:
IRC assessments were done from randomization date until disease progression or death or IRC discontinuation date on 08Feb2019 (as the IA based on this data cutoff date showed the study crossing superiority boundary) whichever comes first up to 40 months.
Reported as:
Median · Months
Progression-free Survival by IRC Assessment Arm A Versus Arm C
MonthsArm A: Obinutuzumab in Combination With ChlorambucilArm C: Acalabrutinib Monotherapy
Progression-free Survival by IRC Assessment Arm A Versus Arm C22.6 (20.2 to 27.6)NA (34.2 to NA)
Statistical analysis
  • Arm A: Obinutuzumab in Combination With Chlorambucil vs Arm C: Acalabrutinib Monotherapy · Log Rank · p = <0.0001 · Hazard ratio (hr): 0.2 · 95% CI 0.13 to 0.30Stratified by randomization stratification factors as recorded in IXRS
SecondaryIRC-assessed Objective Response Rate (ORR) in Arm A Versus Arm B and Arm A Versus Arm C

ORR was defined as the proportion of subjects who achieved a best response of CR, CRi, nPR, or PR at or before initiation of subsequent anticancer therapy. ORR including PRL was defined as the proportion of subjects who achieved a best response of CR, CRi, nPR, PR or PRL at or before initiation of subsequent anticancer therapy

Time frame:
IRC assessments were done from randomization date until disease progression or death or IRC discontinuation date on 08Feb2019 (as the IA based on this data cutoff date showed the study crossing superiority boundary) whichever comes first up to 40 months.
Reported as:
Number · percentage of participants
IRC-assessed Objective Response Rate (ORR) in Arm A Versus Arm B and Arm A Versus Arm C
percentage of participantsArm A: Obinutuzumab in Combination With ChlorambucilArm B: Acalabrutinib in Combination With ObinutuzumabArm C: Acalabrutinib Monotherapy
IRC-assessed Objective Response Rate (ORR) in Arm A Versus Arm B and Arm A Versus Arm C78.5 (71.9 to 83.9)93.9 (89.3 to 96.5)85.5 (79.6 to 89.9)
Statistical analysis
  • Arm A: Obinutuzumab in Combination With Chlorambucil vs Arm B: Acalabrutinib in Combination With Obinutuzumab · Cochran-Mantel-Haenszel · p = <0.0001 · Risk difference (rd): 15.3 · 95% CI 8.3 to 22.3Cochran-Mantel-Haenzel test with adjustment for randomization stratification factors as recorded in IXRS
  • Arm A: Obinutuzumab in Combination With Chlorambucil vs Arm C: Acalabrutinib Monotherapy · Cochran-Mantel-Haenszel · p = 0.0763 · Risk difference (rd): 6.9 · 95% CI -1.0 to 14.9Cochran-Mantel-Haenzel test with adjustment for randomization stratification factors as recorded in IXRS.
SecondaryTime to Next Treatment (TTNT) in Arm A Versus Arm B and Arm A Versus Arm C

TTNT was defined as the time from randomization to start date of non-protocol specified subsequent anticancer therapy for CLL or death due to any cause, whichever came first. TTNT was analyzed in the same fashion as that for the primary efficacy analysis

Time frame:
From randomization date to start of non-protocol specified subsequent anticancer therapy for CLL or death due to any cause, whichever came first assessed up to 40 months of follow-up.
Reported as:
Median · Months
Time to Next Treatment (TTNT) in Arm A Versus Arm B and Arm A Versus Arm C
MonthsArm A: Obinutuzumab in Combination With ChlorambucilArm B: Acalabrutinib in Combination With ObinutuzumabArm C: Acalabrutinib Monotherapy
Time to Next Treatment (TTNT) in Arm A Versus Arm B and Arm A Versus Arm CNA (28.9 to NA)NA (NA to NA)NA (NA to NA)
Statistical analysis
  • Arm A: Obinutuzumab in Combination With Chlorambucil vs Arm B: Acalabrutinib in Combination With Obinutuzumab · Log Rank · p = <0.0001 · Hazard ratio (hr): 0.14 · 95% CI 0.08 to 0.26Stratified by randomization stratification factors as recorded in IXRS
  • Arm A: Obinutuzumab in Combination With Chlorambucil vs Arm C: Acalabrutinib Monotherapy · Log Rank · p = <0.0001 (P-value based on stratified by randomization stratification factors as recorded in IXRS) · Hazard ratio (hr): 0.24 · 95% CI 0.15 to 0.40Stratified by randomization stratification factors as recorded in IXRS
SecondaryOverall Survival (OS) in Arm A Versus Arm B and Arm A Versus Arm C

OS was defined as the time from the date of randomization to death due to any cause.

Time frame:
From randomization date until death, withdrawal by subject, lost to follow-up, or by analysis data cut off date on 08Feb2019 whichever comes first up to 40 months of follow-up.
Reported as:
Median · Months
Overall Survival (OS) in Arm A Versus Arm B and Arm A Versus Arm C
MonthsArm A: Obinutuzumab in Combination With ChlorambucilArm B: Acalabrutinib in Combination With ObinutuzumabArm C: Acalabrutinib Monotherapy
Overall Survival (OS) in Arm A Versus Arm B and Arm A Versus Arm CNA (NA to NA)NA (NA to NA)NA (NA to NA)
Statistical analysis
  • Arm A: Obinutuzumab in Combination With Chlorambucil vs Arm B: Acalabrutinib in Combination With Obinutuzumab · Log Rank · p = 0.0577 · Hazard ratio (hr): 0.47 · 95% CI 0.21 to 1.06Stratified by randomization stratification factors as recorded in IXRS
  • Arm A: Obinutuzumab in Combination With Chlorambucil vs Arm C: Acalabrutinib Monotherapy · Log Rank · p = 0.1556 · Hazard ratio (hr): 0.60 · 95% CI 0.28 to 1.27Stratified by randomization stratification factors as recorded in IXRS

Adverse events

Collected over All adverse events were reported from randomization date until 30 days after the last dose of study drug or the start of new anticancer therapy (whichever comes first) up to 61 months. After this period, investigators reported SAEs or other AEs of concern that are believed to be related to prior treatment with study drug up to 5 years.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Arm A: Obinutuzumab in Combination With Chlorambucil17/177 (9.6%)37/169 (21.9%)167/169 (98.8%)
Arm B: Acalabrutinib in Combination With Obinutuzumab9/179 (5%)69/178 (38.8%)171/178 (96.1%)
Arm C: Acalabrutinib Monotherapy11/179 (6.1%)57/179 (31.8%)170/179 (95%)
Arm A Cross-over: Obinutuzumab+Chlorambucil Crossover to Acalabrutinib Monotherapy2/45 (4.4%)6/45 (13.3%)37/45 (82.2%)
Most frequent serious events
Showing 10 of 173
Most frequent serious events
EventArm A: Obinutuzumab in Combination With ChlorambucilArm B: Acalabrutinib in Combination With ObinutuzumabArm C: Acalabrutinib MonotherapyArm A Cross-over: Obinutuzumab+Chlorambucil Crossover to Acalabrutinib Monotherapy
PneumoniaInfections and infestations3/16912/1785/1790/45
Tumour lysis syndromeMetabolism and nutrition disorders8/1691/1780/1790/45
Febrile neutropeniaBlood and lymphatic system disorders7/1693/1782/1791/45
Infusion related reactionInjury, poisoning and procedural complications2/1694/1780/1790/45
AnaemiaBlood and lymphatic system disorders0/1693/1784/1790/45
Acute myocardial infarctionCardiac disorders1/1691/1783/1791/45
Upper respiratory tract infectionInfections and infestations1/1690/1780/1791/45
OsteoarthritisMusculoskeletal and connective tissue disorders0/1691/1780/1791/45
NauseaGastrointestinal disorders0/1690/1780/1791/45
Malignant melanomaNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/1690/1780/1791/45
Most frequent other events
Showing 10 of 55
Most frequent other events
EventArm A: Obinutuzumab in Combination With ChlorambucilArm B: Acalabrutinib in Combination With ObinutuzumabArm C: Acalabrutinib MonotherapyArm A Cross-over: Obinutuzumab+Chlorambucil Crossover to Acalabrutinib Monotherapy
NeutropeniaBlood and lymphatic system disorders76/16956/17819/1791/45
HeadacheNervous system disorders20/16971/17866/17910/45
Infusion related reactionInjury, poisoning and procedural complications67/16924/1780/1791/45
DiarrhoeaGastrointestinal disorders36/16969/17862/1798/45
NauseaGastrointestinal disorders53/16936/17840/1799/45
FatigueGeneral disorders29/16950/17833/1796/45
ContusionInjury, poisoning and procedural complications7/16942/17827/1795/45
ArthralgiaMusculoskeletal and connective tissue disorders8/16939/17828/1793/45
CoughRespiratory, thoracic and mediastinal disorders15/16939/17833/1797/45
Upper respiratory tract infectionInfections and infestations14/16938/17833/1796/45

Baseline characteristics

Analysis was performed on intent-to-treat (ITT) population, which included all randomized participants grouped according to assigned treatment.

Age, Categorical
Age, Categorical(Participants)Obinutuzumab in Combination With ChlorambucilAcalabrutinib in Combination With ObinutuzumabAcalabrutinib MonotherapyTotal
<=18 years0000
Between 18 and 65 years24352887
>=65 years153144151448
Sex: Female, Male
Sex: Female, Male(Participants)Obinutuzumab in Combination With ChlorambucilAcalabrutinib in Combination With ObinutuzumabAcalabrutinib MonotherapyTotal
Female716868207
Male106111111328
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Obinutuzumab in Combination With ChlorambucilAcalabrutinib in Combination With ObinutuzumabAcalabrutinib MonotherapyTotal
Hispanic or Latino1121124
Not Hispanic or Latino156169156481
Unknown or Not Reported1081230
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Obinutuzumab in Combination With ChlorambucilAcalabrutinib in Combination With ObinutuzumabAcalabrutinib MonotherapyTotal
American Indian or Alaska Native1001
Asian0303
Native Hawaiian or Other Pacific Islander1001
Black or African American45413
White165164170499
More than one race0000
Unknown or Not Reported67518
Region of Enrollment
Region of Enrollment(Participants)Obinutuzumab in Combination With ChlorambucilAcalabrutinib in Combination With ObinutuzumabAcalabrutinib MonotherapyTotal
Belgium55313
France3317
Germany3137
Italy119525
Spain73313
Sweden1337
United Kingdom12161745
Brazil45514
Chile2035
Colombia1001
Canada78722
United States545663173
Hungary17261558
Lithuania92617
Poland14202559
Australia99826
New Zealand84517
Israel109726
IXRS Randomization Stratification Factor: Presence of 17p Deletion
IXRS Randomization Stratification Factor: Presence of 17p Deletion(Participants)Obinutuzumab in Combination With ChlorambucilAcalabrutinib in Combination With ObinutuzumabAcalabrutinib MonotherapyTotal
Yes17211957
No160158160478
IXRS Randomization Stratification Factor: ECOG Performance Status
IXRS Randomization Stratification Factor: ECOG Performance Status(Participants)Obinutuzumab in Combination With ChlorambucilAcalabrutinib in Combination With ObinutuzumabAcalabrutinib MonotherapyTotal
0-1 (0=Fully Active; 1 =Restricted in Physically Strenuous Activity)168169167504
2 (2=Ambulatory and capable of all selfcare but unable to carry out any work activities)9101231
IXRS Randomization Stratification Factor: Geographic Region
IXRS Randomization Stratification Factor: Geographic Region(Participants)Obinutuzumab in Combination With ChlorambucilAcalabrutinib in Combination With ObinutuzumabAcalabrutinib MonotherapyTotal
North America and West Europe103104105312
Other747574223
08

Study locations

155 sites
  • Research Site
    Goodyear, Arizona 85395, United States
  • Research Site
    Phoenix, Arizona 85016, United States
  • Research Site
    Anaheim, California 92801, United States
  • Research Site
    Los Angeles, California 90017, United States
  • Research Site
    Los Angeles, California 90033, United States
  • Research Site
    Los Angeles, California 90095, United States
  • Research Site
    Oxnard, California 93030, United States
  • Research Site
    Palo Alto, California 94304, United States
  • Research Site
    Aurora, Colorado 80045, United States
  • Research Site
    Lone Tree, Colorado 80124, United States
  • Research Site
    Washington D.C., District of Columbia 20007, United States
  • Research Site
    Fort Myers, Florida 33901-8101, United States
  • Research Site
    Jacksonville, Florida 32224, United States
  • Research Site
    Tallahassee, Florida 32308-5304, United States
  • Research Site
    Tallahassee, Florida 32308, United States
  • Research Site
    Tampa, Florida 33612, United States
  • Research Site
    Niles, Illinois 60714, United States
  • Research Site
    Lafayette, Indiana 47904, United States
  • Research Site
    Wichita, Kansas 67214, United States
  • Research Site
    Louisville, Kentucky 40207, United States
  • Research Site
    New Orleans, Louisiana 70112, United States
  • Research Site
    COL, Maryland 21044, United States
  • Research Site
    Rochester, Minnesota 55905, United States
  • Research Site
    Saint Cloud, Minnesota 56303, United States
  • Research Site
    Billings, Montana 59102, United States
  • Research Site
    Brick, New Jersey 08724, United States
  • Research Site
    Hackensack, New Jersey ?07601, United States
  • Research Site
    Lake Success, New York 11042, United States
  • Research Site
    New York, New York 10029, United States
  • Research Site
    Blue Ash, Ohio 45242, United States
  • Research Site
    Canton, Ohio 44719, United States
  • Research Site
    Columbus, Ohio 43210, United States
  • Research Site
    Nashville, Tennessee 37203, United States
  • Research Site
    Austin, Texas 78705, United States
  • Research Site
    Bedford, Texas 76022, United States
  • Research Site
    Dallas, Texas 75230, United States
  • Research Site
    Fort Sam Houston, Texas 78234, United States
  • Research Site
    Houston, Texas 77030, United States
  • Research Site
    New Braunfels, Texas 78130, United States
  • Research Site
    Round Rock, Texas 76508, United States
  • Research Site
    San Antonio, Texas 78258, United States
  • Research Site
    Texas City, Texas 77591, United States
  • Research Site
    Tyler, Texas 75702, United States
  • Research Site
    Salt Lake City, Utah 84112, United States
  • Research Site
    Roanoke, Virginia 24014, United States
  • Research Site
    Seattle, Washington 98109, United States
  • Research Site
    Seattle, Washington 98122, United States
  • Research Site
    Spokane, Washington 99208, United States
  • Research Site
    Tacoma, Washington 98405, United States
  • Research Site
    Yakima, Washington 98902, United States
  • Research Site
    Northwest WA, Wisconsin 20007, United States
  • Research Site
    Darlinghurst, 2010, Australia
  • Research Site
    Frankston, 3199, Australia
  • Research Site
    Geelong, 3220, Australia
  • Research Site
    South Brisbane, QLD 4101, Australia
  • Research Site
    Waratah NSW, 2298, Australia
  • Research Site
    Wollongong, 2500, Australia
  • Research Site
    Woodville, 5011, Australia
  • Research Site
    Bruges, 8000, Belgium
  • Research Site
    Brussels, 1090, Belgium
  • Research Site
    Brussels, 1200, Belgium
  • Research Site
    Ghent, 9000, Belgium
  • Research Site
    Kortrijk, 8500, Belgium
  • Research Site
    Leuven, 3000, Belgium
  • Research Site
    Roeselare, 8900, Belgium
  • Research Site
    Wilrijk, 2610, Belgium
  • Research Site
    Yvoir, 5530, Belgium
  • Research Site
    Barretos, 14784-400, Brazil
  • Research Site
    Florianópolis, 88034-000, Brazil
  • Research Site
    Passo Fundo, 99010-260, Brazil
  • Research Site
    Porto Alegre, 90035-903, Brazil
  • Research Site
    Porto Alegre, 90470-340, Brazil
  • Research Site
    São Paulo, 155, Brazil
  • Research Site
    Vancouver, British Columbia V5Z 4E6, Canada
  • Research Site
    Halifax, Nova Scotia B3H2Y9, Canada
  • Research Site
    Québec, G1J 1Z4, Canada
  • Research Site
    Saint John, E2L 4L2, Canada
  • Research Site
    Winnipeg, R3E 0V9, Canada
  • Research Site
    Santiago, 8380455, Chile
  • Research Site
    Temuco, 4810469, Chile
  • Research Site
    Medellín, 050034, Colombia
  • Research Site
    Montería, 110221, Colombia
  • Research Site
    Bobigny, 93000, France
  • Research Site
    Dijon, 21000, France
  • Research Site
    Pierre-Bénite, 69310, France
  • Research Site
    Strasbourg, 67098, France
  • Research Site
    Villejuif, 94800, France
  • Research Site
    Aschaffenburg, 63739, Germany
  • Research Site
    Bielefeld, 33604, Germany
  • Research Site
    Erlangen, 91052, Germany
  • Research Site
    Heilbronn, 74078, Germany
  • Research Site
    Warzburg, 97080, Germany
  • Research Site
    Budapest, 1085, Hungary
  • Research Site
    Budapest, 1122, Hungary
  • Research Site
    Debrecen, 4032, Hungary
  • Research Site
    Kaposvár, 7400, Hungary
  • Research Site
    Szolnok, 5004, Hungary
  • Research Site
    Ashkelon, 7830604, Israel
  • Research Site
    Beersheba, 84101, Israel
  • Research Site
    Haifa, 31000, Israel

Showing the first 100 of 155 sites across 18 countries. Choose a country and city above to see the rest.

09

References and documents

Publications

  • Sharman JP, Egyed M, Jurczak W, Skarbnik A, Patel K, Flinn IW, Kamdar M, Munir T, Walewska R, Hughes M, Fogliatto LM, Herishanu Y, Banerji V, Follows G, Walker P, Ghia P, Janssens A, Byrd JC, Ferrant E, Ferrajoli A, Wierda WG, Wachira CW, Suterwala BT, Miranda P, Munugalavadla V, Wun CC, Woyach JA. Acalabrutinib-obinutuzumab improves survival vs chemoimmunotherapy in treatment-naive CLL in the 6-year follow-up of ELEVATE-TN. Blood. 2025 Sep 11;146(11):1276-1285. doi: 10.1182/blood.2024024476. PubMed 40198878 ↗
  • Kittai AS, Allan JN, James D, Bridge H, Miranda M, Yong ASM, Fam F, Roos J, Shetty V, Skarbnik A, Davids MS. An indirect comparison of acalabrutinib with and without obinutuzumab vs zanubrutinib in treatment-naive CLL. Blood Adv. 2024 Jun 11;8(11):2861-2869. doi: 10.1182/bloodadvances.2023012142. PubMed 38598745 ↗
  • Sharman JP, Egyed M, Jurczak W, Skarbnik A, Pagel JM, Flinn IW, Kamdar M, Munir T, Walewska R, Corbett G, Fogliatto LM, Herishanu Y, Banerji V, Coutre S, Follows G, Walker P, Karlsson K, Ghia P, Janssens A, Cymbalista F, Woyach JA, Salles G, Wierda WG, Izumi R, Munugalavadla V, Patel P, Wang MH, Wong S, Byrd JC. Acalabrutinib with or without obinutuzumab versus chlorambucil and obinutuzmab for treatment-naive chronic lymphocytic leukaemia (ELEVATE TN): a randomised, controlled, phase 3 trial. Lancet. 2020 Apr 18;395(10232):1278-1291. doi: 10.1016/S0140-6736(20)30262-2. PubMed 32305093 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal. All request will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure. Yes, indicates that AZ are accepting requests for IPD, but this does not mean all requests will be shared.

Supporting information: Study protocol, Statistical analysis plan

Time frame: AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA Pharma Data Sharing Principles. For details of our timelines, please rerefer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

Access criteria: When a request has been approved AstraZeneca will provide access to the deidentified individual patient-level data in an approved sponsored tool . Signed Data Sharing Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information. Additionally, all users will need to accept the terms and conditions of the SAS MSE to gain access. For additional details, please review the Disclosure Statements at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

Data sharing details ↗ · astrazenecagroup-dt.pharmacm.com

10

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jun 2015 to primary completion in Feb 2019, 43 months.

Results were first posted in Jan 2023, 3 years 11 months after primary completion.

Of 57 industry-sponsored phase 3 interventional studies under Leukemia, Lymphocytic, Chronic, B-Cell, half reached primary completion within 53 months of starting (the median), counting those still running; a quarter within 41 and three quarters within 73. This study's 43 months is below that.

Counting every sponsor, half of 83 studies reached it within 59 months; a quarter within 43 and three quarters within 76.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 12, 2015
First posted
Jun 19, 2015
StartActual
Jun 26, 2015
Primary completionActual
Feb 8, 2019
CompletionActual
Sep 3, 2026
Results first posted
Jan 10, 2023
Last update
Nov 16, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Active, not recruiting→Completed
changed Nov 16, 2026
Sites
1 site added, 1 site removed
Show site
  • Research Site · Tel HaShomer, Israel
Show 1 removed
  • Research Site · Qiryat Krinitzi, Israel
Nov 16, 2026
Study completion
Sep 15, 2026→Sep 3, 2026 (actual)
Nov 16, 2026
Show all 1 update
  1. Nov 16, 2026
    Active, not recruiting→Completed
    1 site added, 1 site removed
    Show site
    • Research Site · Tel HaShomer, Israel
    Show 1 removed
    • Research Site · Qiryat Krinitzi, Israel
    Study completion Sep 15, 2026→Sep 3, 2026 (now actual)
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

11

Registry details

Key details

Study ID
NCT02475681
Lead sponsor
Acerta Pharma BV
Responsible party
Sponsor
First posted
Jun 19, 2015
Start date
Jun 26, 2015
Primary completion
Feb 8, 2019
Completion
Sep 3, 2026
Results posted
Jan 10, 2023
Last update
Nov 16, 2026

Study contacts

AstraZeneca Clinical Study Information Center
study director · 1-877-240-9479 information.center@astrazeneca.com

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Acalabrutinib · Obinutuzumab

Start the discussion